肿瘤学临床试验中的患者报告结局：2019 年加速抗癌药物研发和验证研讨会的利益相关者观点。
Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019.
机构信息
Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Quantitative Science, Clinical Outcomes Solutions, Tucson, Arizona, USA.
出版信息
Oncologist. 2020 Oct;25(10):819-821. doi: 10.1634/theoncologist.2020-0062. Epub 2020 Jun 9.
Abstract
The measurement and analysis of patient‐reported outcomes is important in cancer clinical trials. This commentary reports advances and challenges from presentations at the 2019 Accelerating Anticancer Agent Development and Validation (AAADV) Workshop Patient‐Reported Outcomes Session.
摘要
患者报告结局的测量和分析在癌症临床试验中很重要。本篇述评报道了在 2019 年加速抗癌药物开发和验证（AAADV）研讨会患者报告结局会议上的演讲所取得的进展和面临的挑战。
相似文献
1
Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019.肿瘤学临床试验中的患者报告结局：2019 年加速抗癌药物研发和验证研讨会的利益相关者观点。
Oncologist. 2020 Oct;25(10):819-821. doi: 10.1634/theoncologist.2020-0062. Epub 2020 Jun 9.
2
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.使用患者报告的结局测量来告知癌症治疗的耐受性：FDA 和关键路径研究所研讨会的总结。
Value Health. 2018 Jun;21(6):742-747. doi: 10.1016/j.jval.2017.09.009. Epub 2017 Nov 7.
3
Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials-Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop.促进肿瘤登记试验中多样性、市场准入和能力的行动——非洲是答案吗？在加速抗癌药物研发和验证研讨会上的卫星会议报告。
JCO Glob Oncol. 2022 Jun;8:e2200117. doi: 10.1200/GO.22.00117.
4
Optimizing electronic capture of patient-reported outcome measures in oncology clinical trials: lessons learned from a qualitative study.优化肿瘤临床试验中患者报告结局测量的电子采集：来自定性研究的经验教训。
J Comp Eff Res. 2020 Dec;9(17):1195-1204. doi: 10.2217/cer-2020-0143. Epub 2020 Dec 4.
5
Demystifying the estimand framework: a case study using patient-reported outcomes in oncology.揭开估计量框架的神秘面纱：以肿瘤患者报告结局为例的研究。
Lancet Oncol. 2020 Oct;21(10):e488-e494. doi: 10.1016/S1470-2045(20)30319-3.
6
Results from a 1-day workshop on the assessment of quality of life in cancer patients: a joint initiative of the Japan Clinical Oncology Group and the European Organisation for Research and Treatment of Cancer.为期一天的癌症患者生活质量评估研讨会的结果：日本临床肿瘤学会与欧洲癌症研究与治疗组织的联合倡议。
Jpn J Clin Oncol. 2020 Oct 22;50(11):1333-1341. doi: 10.1093/jjco/hyaa119.
7
The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials.在肿瘤 I 期临床试验中使用患者报告结局测量。
Oncology. 2021;99(7):444-453. doi: 10.1159/000514874. Epub 2021 Apr 6.
8
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?药物基因组学在早期肿瘤临床试验中的应用：在 II 期临床试验中是否存在一个最佳时机？
Clin Cancer Res. 2012 May 15;18(10):2809-16. doi: 10.1158/1078-0432.CCR-11-2445. Epub 2012 Mar 16.
9
Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.将儿童和青少年自我报告的症状数据与临床医生报告的不良事件分级进行映射，以改善儿科肿瘤学的护理和研究。
Cancer. 2020 Jan 1;126(1):140-147. doi: 10.1002/cncr.32525. Epub 2019 Sep 25.
10
Accelerating anticancer drug development - opportunities and trade-offs.加速抗癌药物研发——机遇与权衡。
Nat Rev Clin Oncol. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3.
引用本文的文献
1
Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.在一项 II 期临床试验中，接受西普单抗治疗的局部晚期基底细胞癌患者的生活质量。
Future Oncol. 2024;20(30):2249-2258. doi: 10.1080/14796694.2024.2358670. Epub 2024 Jul 29.
2
Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research.弥合统计学显著性与临床相关性之间的差距：运动障碍研究中报告的量表最小临床重要差异（MCID）阈值的系统评价
Heliyon. 2024 Feb 20;10(5):e26479. doi: 10.1016/j.heliyon.2024.e26479. eCollection 2024 Mar 15.
3
Minimal Clinically Important Difference (MCID) in Patient-Reported Outcome Measures for Neurological Conditions: Review of Concept and Methods.神经疾病患者报告结局测量中的最小临床重要差异（MCID）：概念与方法综述
Ann Indian Acad Neurol. 2023 Jul-Aug;26(4):334-343. doi: 10.4103/aian.aian_207_23. Epub 2023 Jun 12.
4
Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer.采用定性访谈的方法，确定对晚期乳腺癌患者最有意义的患者报告的临床试验结局和分析。
PLoS One. 2023 Jan 17;18(1):e0280259. doi: 10.1371/journal.pone.0280259. eCollection 2023.
5
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.E2112：内分泌治疗联合恩替诺特或安慰剂治疗激素受体阳性晚期乳腺癌的随机 III 期试验。ECOG-ACRIN 癌症研究组的一项试验。
J Clin Oncol. 2021 Oct 1;39(28):3171-3181. doi: 10.1200/JCO.21.00944. Epub 2021 Aug 6.
本文引用的文献
1
Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer.晚期肺癌患者对化疗治疗方案的偏好和对化疗副作用的耐受性。
BMC Cancer. 2019 Aug 27;19(1):835. doi: 10.1186/s12885-019-6054-x.
2
Fit for purpose and modern validity theory in clinical outcomes assessment.适用于临床结局评估的目的和现代效度理论。
Qual Life Res. 2018 Jul;27(7):1711-1720. doi: 10.1007/s11136-017-1644-z. Epub 2017 Jul 7.
3
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.关注癌症临床试验中的核心患者报告结局：症状性不良事件、身体功能和疾病相关症状。
Clin Cancer Res. 2016 Apr 1;22(7):1553-8. doi: 10.1158/1078-0432.CCR-15-2035. Epub 2016 Jan 12.
4
Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the Patient.癌症药物研发和美国监管审查中的患者报告结局：来自工业界、美国食品和药物管理局以及患者的观点。
JAMA Oncol. 2015 Jun;1(3):375-9. doi: 10.1001/jamaoncol.2015.0530.
5
Toward patient-centered drug development in oncology.迈向肿瘤学中以患者为中心的药物研发。
N Engl J Med. 2013 Aug 1;369(5):397-400. doi: 10.1056/NEJMp1114649. Epub 2013 Jul 3.
Zotero 插件